Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry

@article{Hernndez2018FactorsAW,
  title={Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry},
  author={Mar{\'i}a Victoria Hern{\'a}ndez and Carlos S{\'a}nchez-Piedra and Blanca Garc{\'i}a-Magall{\'o}n and Eduardo Cuende and J. A. L{\'a}zaro Manero and Cristina Campos-Fern{\'a}ndez and Raquel Mart{\'i}n-Domenech and Javier del Pino-Montes and S. J. Gonz{\'a}lez Manrique and Mar{\'i}a del Carmen Castro-Villegas and Dolores Ruiz-Montesinos and Fernando S{\'a}nchez-Alonso and Federico D{\'i}az-Gonz{\'a}lez and Luis Cea-Calvo and Juan J G{\'o}mez-Reino},
  journal={Rheumatology International},
  year={2018},
  volume={39},
  pages={509-515}
}
The retention rate of a biological drug (percentage of patients remaining on treatment over time) provides an index of a drug’s overall effectiveness. The golimumab retention rate as first-line biological therapy was high in clinical trial extensions lasting 5 years. Real-world studies also indicate good retention rates but have been of shorter duration. The probability of retention with golimumab treatment was assessed, as any line of anti-tumor necrosis factor-alpha therapy, for up to 5 years… CONTINUE READING
BETA
2
Twitter Mentions

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES